Author

Han Na Kim

EXPOSURE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) IN PATIENTS WITH ACTIVE CROHN'S DISEASE AND ULCERATIVE COLITIS: ANALYSIS FROM A MULTICENTER, RANDOMIZED CONTROLLED PIVOTAL TRIAL

Byong Duk Ye, Jaroslaw Leszczyszyn, Robert Dudkowiak, Adi Lahat, Beata Gawdis-Wojnarska, Aldis Pukitis, Marek Horynski, Katalin Farkas, Jaroslaw Kierkuś, Maciej Kowalski, Stefan Schreiber, Walter Reinisch, Sang Joon Lee, Sung Hyun Kim, Jee Hye Suh, Mi Rim Kim, Han Na Kim, Shomron Ben-Horin

Noninferiority of Novel Subcutaneous Infliximab (CT-P13) to Intravenous Infliximab (CT-P13) in Patients with Active Crohn's Disease and Ulcerative Colitis: Week 30 Results from a Multicentre, Randomised Controlled Pivotal Trial

Stefan Schreiber, Jaroslaw Leszczyszyn, Robert Dudkowiak, Adi Lahat, Beata Gawdis-Wojnarska, Aldis Pukitis, Marek Horynski, Katalin Farkas, Jaroslaw Kierkuś, Maciej Kowalski, Shomron Ben-Horin, Byong Duk Ye, Sang Joon Lee, Sung Hyun Kim, Mi Rim Kim, Han Na Kim, Walter Reinisch

Item 1 - 2 / 2
1